Telesis Bio Inc.
0.41
0.08 (23.94%)
At close: Jan 14, 2025, 8:00 PM
2.85
593.43%
After-hours Sep 27, 2024, 07:59 PM EDT

Company Description

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.

Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

It also serves government institutions, contract research organizations, and synthetic biology companies.

The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020.

Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Telesis Bio Inc.
Telesis Bio Inc. logo
Country United States
IPO Date Jun 18, 2021
Industry Medical - Devices
Sector Healthcare
Employees 137
CEO Eric Esser

Contact Details

Address:
29 Hartwell Ave
Lexington, MASSACHUSETTS
United States
Website https://codexdna.com

Stock Details

Ticker Symbol TBIO
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001693415
CUSIP Number 89374L104
ISIN Number US1920031010
Employer ID 61-1807780
SIC Code 2836

Key Executives

Name Position
Eric Esser President, Chief Executive Officer, Chief Operating Officer & Chairman
Daniel G. Gibson Ph.D. Chief Technology Officer
William J. Kullback Chief Financial Officer
Decky Goodrich M.B.A. Senior Vice President of Corporate Development
Jen Carroll Vice President of Investor Relations
Richard Lepke Director of Investor Relations

Latest SEC Filings

Date Type Title
Sep 24, 2021 15-12B Filing
Sep 21, 2021 EFFECT Filing
Sep 21, 2021 EFFECT Filing
Sep 16, 2021 4/A [Amend] Filing
Sep 16, 2021 SC 13D/A [Amend] Filing
Sep 14, 2021 4 Filing
Sep 14, 2021 4 Filing
Sep 14, 2021 4 Filing
Sep 14, 2021 4/A [Amend] Filing
Sep 14, 2021 4 Filing